Q-omics provides the consensus-scored NME1-NME2 profile across patient tissues and cancer cell-line models. NME1-NME2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NME1-NME2 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, NME1-NME2 RNA expression shows 16,333 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BLCA, COAD, and ACC as cancer lineages where NME1-NME2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NME1-NME2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NME1-NME2 survival associations across molecular data types. NME1-NME2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NME1-NME2 RNA expression–survival associations across cancer types. High NME1-NME2 expression shows unfavorable associations in BLCA, KIRC, MESO, PAAD, KICH and UVM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BLCA as the clearest survival context for NME1-NME2 RNA expression.
This table summarizes NME1-NME2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NME1-NME2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NME1-NME2 shows higher tumor expression in COAD, KIRP, LUAD, KIRC, LUSC and HNSC. The COAD box plot shows higher NME1-NME2 RNA expression in tumor versus normal tissue (log2 FC = +1.291, t-test p < 0.001).
This table shows molecular features associated with NME1-NME2 in patient tissues and cancer cell lines. In patient samples, NME1-NME2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NME1-NME2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN.
